Table 1 Characteristics of the study group
JIA | All patients (N = 70, 100%) | Newly diagnosed (N = 59, 84.3%) | Biologically treated (N = 11, 15.7%) | p value |
|---|---|---|---|---|
Sex | ||||
Girls | 51 (72.9%) | 43 (72.9%) | 8 (72.7%) | |
Boys | 19 (27.1%) | 16 (27.1%) | 3 (27.3%) | 1.000 |
Age [years] | 10.25 (6.5–15.5) | 9.0 (5.5–14.5) | 17.0 (14.5–17.5) | < 0.001 |
Age at onset [years] | 7.00 (3.5–12.5) | 7.5 (4.0–13.5) | 4.0 (2.0–10.0) | 0.095 |
Disease duration time [months] | 6.0 (1.5–36.0) | 3.0 (1.0–18.0) | 84.0 (72.0–132.0) | < 0.001 |
Disease onset type | ||||
Oligoarthritis | 46 (65.7%) | 41 (69.5%) | 5 (45.5%) | |
Polyarthritis | 23 (32.9%) | 18 (30.5%) | 5 (45.5%) | 0.073 |
Systemic | 1 (1.4%) | 0 (0%) | 1 (9%) | |
Disease activity (JADAS-27) | ||||
Low/medium/high | 44 (62.9%) | 36 (61.0%) | 8 (72.7%) | 1.000 |
17 (24.3%) | 14 (23.7%) | 3 (27.3%) | ||
9 (12.86%) | 9 (15.3%) | 0 (0%) | ||
WBC [G/L] | 7.25 (5.6–9.6) | 7.2 (5.5–10.7) | 7.7 (6.2–9.2) | 0.675 |
PLT [G/L] | 328.0 (254.0–420.0) | 348.0 (269.0–425.0) | 228.0 (206.0–349.0) | 0.006 |
ESR [mm/h] | 13.0 (7.0–25.0) | 15.0 (8.0–35.0) | 6.0 (3.0–15.0) | 0.007 |
CRP [N < 5.0 mg/dl] | 1.6 (0.4–8.9) | 2.0 (0.4–11.8) | 0.4 (0.2–2.7) | 0.057 |
ACPA (anti-CCP) > 5 mg/dl | 17 (24.3%) | 13 (22.0%) | 4 (36.4%) | 0.443 |
ANA ≥ 1:160 | 33 (47.1%) | 32 (54.2%) | 1 (9%) | 0.007 |
RF > 14 IU | 9 (12.9%) | 5 (8.5%) | 4 (36.4%) | 0.029 |
Hands X-ray | Stage 1–49 (70.0%) | 44 (74.6%) | 5 (45.5%) | 0.099 |
Stage 2–14 (20.0%) | 10 (16.9%) | 4 (36.4%) | ||
Stage 3–7 (10.0%) | 5 (8.5%) | 2 (18.2%) | ||
Joint US - PDUS | Grade 0–11 (15.7%) | 5 (8.5%) | 6 (54.5%) | < 0.001 |
Grade 1–20 (28.6%) | 15 (25.4%) | 5 (45.5%) | ||
Grade 2–20 (28.6%) | 20 (33.9%) | 0 (0%) | ||
Grade 3–19 (27.1%) | 19 (32.2%) | 0 (0%) | ||